BridgeBio Pharma Balance Sheet Health
Financial Health criteria checks 1/6
BridgeBio Pharma has a total shareholder equity of $-1.9B and total debt of $1.9B, which brings its debt-to-equity ratio to -96.3%. Its total assets and total liabilities are $998.3M and $2.9B respectively.
Key information
-96.27%
Debt to equity ratio
US$1.85b
Debt
| Interest coverage ratio | n/a |
| Cash | US$645.94m |
| Equity | -US$1.92b |
| Total liabilities | US$2.92b |
| Total assets | US$998.25m |
Recent financial health updates
No updates
Recent updates
BridgeBio Has More Room To Run
Dec 23
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 09
Pinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right Now
Apr 28BridgeBio: Early Signs Point To Blockbuster Revenues
Apr 22BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
Feb 07BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
Jan 15BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jan 12BridgeBio: Next Chapter Begins After Attruby Approval
Nov 24BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
Aug 31BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
Aug 17BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03Financial Position Analysis
Short Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BBIO has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BBIO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 06:30 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Pharma, Inc. is covered by 33 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Pickering | Bernstein |
| Jason Zemansky | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |